Published in J Neuroimmunol on August 10, 2005
Sorting out the functional role(s) of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) in cell proliferation and cancer. Biochim Biophys Acta (2009) 1.51
Modulation of macrophage efferocytosis in inflammation. Front Immunol (2011) 1.40
Peroxisome proliferator-activated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury. J Neurosci (2010) 1.38
PPAR Regulation of Inflammatory Signaling in CNS Diseases. PPAR Res (2008) 1.11
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology (2007) 1.09
Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol Sci (2008) 1.07
Peroxisome Proliferator-Activated Receptor beta/delta in the Brain: Facts and Hypothesis. PPAR Res (2008) 1.05
Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology (2010) 1.01
Neuroprotective Mechanisms of PPARδ: Modulation of Oxidative Stress and Inflammatory Processes. PPAR Res (2011) 1.01
The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells (2012) 1.00
Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J Exp Med (2010) 0.99
Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis. J Neurochem (2011) 0.97
Activation of PPARδ: from computer modelling to biological effects. Br J Pharmacol (2014) 0.97
Effect of pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation (2007) 0.95
MicroRNAs and Multiple Sclerosis. Autoimmune Dis (2010) 0.94
Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors. PPAR Res (2013) 0.94
Impaired clearance of apoptotic cells in chronic inflammatory diseases: therapeutic implications. Front Immunol (2014) 0.93
Chronic expression of PPAR-delta by oligodendrocyte lineage cells in the injured rat spinal cord. J Comp Neurol (2010) 0.92
Acute leptin treatment enhances functional recovery after spinal cord injury. PLoS One (2012) 0.92
Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPARβ/δ: a potential therapeutic role for CNS autoimmune disease. Cell Death Dis (2013) 0.90
Regulation of Glial Cell Functions by PPAR-gamma Natural and Synthetic Agonists. PPAR Res (2008) 0.87
The PPARδ agonist GW0742 inhibits neuroinflammation, but does not restore neurogenesis or prevent early delayed hippocampal-dependent cognitive impairment after whole-brain irradiation. Free Radic Biol Med (2013) 0.85
PPAR-gamma, Microglial Cells, and Ocular Inflammation: New Venues for Potential Therapeutic Approaches. PPAR Res (2008) 0.85
Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination. J Neuroinflammation (2009) 0.85
Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-β. J Biol Chem (2012) 0.85
Nuclear receptors in neurodegenerative diseases. Neurobiol Dis (2014) 0.85
Cellular and Molecular Mechanisms Underpinning Macrophage Activation during Remyelination. Front Cell Dev Biol (2016) 0.84
Integrative and systemic approaches for evaluating PPARβ/δ (PPARD) function. Nucl Recept Signal (2015) 0.84
Activation of the nuclear receptor PPARδ is neuroprotective in a transgenic mouse model of Alzheimer's disease through inhibition of inflammation. J Neuroinflammation (2015) 0.83
Role of PPARs in Radiation-Induced Brain Injury. PPAR Res (2009) 0.83
A peroxisome proliferator-activated receptor-δ agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neuroscience (2013) 0.82
Myelin alters the inflammatory phenotype of macrophages by activating PPARs. Acta Neuropathol Commun (2013) 0.81
Regulation of Immune Responses and Autoimmune Encephalomyelitis by PPARs. PPAR Res (2010) 0.80
Anti-inflammatory and anti-hyperalgesic effect of all-trans retinoic acid in carrageenan-induced paw edema in Wistar rats: involvement of peroxisome proliferator-activated receptor-β/δ receptors. Indian J Pharmacol (2013) 0.80
Effect of NDP-α-MSH on PPAR-γ and -β expression and anti-inflammatory cytokine release in rat astrocytes and microglia. PLoS One (2013) 0.79
Gemfibrozil, a lipid lowering drug, inhibits the activation of primary human microglia via peroxisome proliferator-activated receptor β. Neurochem Res (2012) 0.79
Metabolic and Inflammatory Adaptation of Reactive Astrocytes: Role of PPARs. Mol Neurobiol (2016) 0.78
Regulation of oligodendrocyte progenitor cell maturation by PPARδ: effects on bone morphogenetic proteins. ASN Neuro (2010) 0.78
A role for peroxisome proliferator-activated receptors in the immunopathology of schistosomiasis? PPAR Res (2011) 0.78
Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2016) 0.77
Promoting return of function in multiple sclerosis: An integrated approach. Mult Scler Relat Disord (2013) 0.76
Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficits. Mol Neurobiol (2014) 0.76
PPARdelta status and mismatch repair mediated neoplasia in the mouse intestine. BMC Cancer (2006) 0.76
Importance of Apolipoprotein A-I in Multiple Sclerosis. Front Pharmacol (2015) 0.76
Prophylactic versus Therapeutic Fingolimod: Restoration of Presynaptic Defects in Mice Suffering from Experimental Autoimmune Encephalomyelitis. PLoS One (2017) 0.75
A role for Peroxisome Proliferator-Activated Receptor Beta in T cell development. Sci Rep (2016) 0.75
Sex-specific regulation of immune responses by PPARs. Exp Mol Med (2017) 0.75
Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med (2003) 3.87
Lipid emulsion is superior to vasopressin in a rodent model of resuscitation from toxin-induced cardiac arrest. Crit Care Med (2009) 3.56
Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain. Pain (2005) 3.37
PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci U S A (2006) 3.29
Rapid cardiotonic effects of lipid emulsion infusion*. Crit Care Med (2013) 2.76
Lipid infusion accelerates removal of bupivacaine and recovery from bupivacaine toxicity in the isolated rat heart. Reg Anesth Pain Med (2006) 2.74
PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol (2003) 2.68
Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology (2004) 2.40
Lipid infusion resuscitation for local anesthetic toxicity: proof of clinical efficacy. Anesthesiology (2006) 2.21
Epinephrine impairs lipid resuscitation from bupivacaine overdose: a threshold effect. Anesthesiology (2009) 2.11
Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med (2004) 1.92
Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity. J Lipid Res (2006) 1.88
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol (2002) 1.86
Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A (2007) 1.85
The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation. Cell Signal (2005) 1.64
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem (2007) 1.61
The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol Sci (2005) 1.54
Resuscitation with lipid emulsion: dose-dependent recovery from cardiac pharmacotoxicity requires a cardiotonic effect. Anesthesiology (2014) 1.53
Alterations in skin and stratified epithelia by constitutively activated PPARalpha. J Invest Dermatol (2006) 1.53
Rosiglitazone induces mitochondrial biogenesis in mouse brain. J Alzheimers Dis (2007) 1.53
Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain (2011) 1.50
Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice. Biochem Biophys Res Commun (2008) 1.47
Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci (2002) 1.46
Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res (2006) 1.40
Intravenous lipid emulsion in clinical toxicology. Scand J Trauma Resusc Emerg Med (2010) 1.39
PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis (2004) 1.38
Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver. Crit Rev Toxicol (2006) 1.37
Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. Toxicol Sci (2004) 1.34
Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem (2005) 1.34
PPARbeta/delta potentiates PPARgamma-stimulated adipocyte differentiation. FASEB J (2004) 1.31
Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis (2004) 1.31
Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities. Toxicol Sci (2010) 1.29
Resuscitation with lipid versus epinephrine in a rat model of bupivacaine overdose. Anesthesiology (2008) 1.28
Ligand activation of peroxisome proliferator-activated receptor-beta/delta(PPARbeta/delta) inhibits cell growth of human N/TERT-1 keratinocytes. Cell Signal (2007) 1.26
Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol Pain (2009) 1.24
Deregulation of tumor angiogenesis and blockade of tumor growth in PPARbeta-deficient mice. EMBO J (2007) 1.24
PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene (2004) 1.24
Peroxisome proliferator-activated receptor beta (delta)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J Biol Chem (2004) 1.23
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis (2007) 1.23
Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J Neurosci (2009) 1.22
Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of peroxisome proliferator-activated receptor-alpha. J Biol Chem (2004) 1.22
Nrf2- and PPAR alpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. Toxicol Sci (2008) 1.20
Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro. Eur J Neurosci (2002) 1.20
A novel fluorescent probe that is brain permeable and selectively binds to myelin. J Histochem Cytochem (2006) 1.19
The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro (2011) 1.19
Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis (2007) 1.18
Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem (2002) 1.18
Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int (2002) 1.17
COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J Exp Med (2007) 1.16
Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol (2004) 1.16
Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Hepatology (2008) 1.15
Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol (2006) 1.14
Peroxisome proliferator-activated receptor beta/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet. J Biol Chem (2004) 1.13
P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis. J Neuroinflammation (2008) 1.12
Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging (2006) 1.11
The clinical course of experimental autoimmune encephalomyelitis is associated with a profound and sustained transcriptional activation of the genes encoding toll-like receptor 2 and CD14 in the mouse CNS. Brain Pathol (2002) 1.10
Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of anti-inflammatory properties. J Neurochem (2005) 1.10
Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology (2007) 1.09
Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway. Circulation (2008) 1.09
Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol Sci (2008) 1.07
Lipid, not propofol, treats bupivacaine overdose. Anesth Analg (2004) 1.06
The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes. J Neuroinflammation (2011) 1.05
The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurochem (2006) 1.04
Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients. J Leukoc Biol (2003) 1.04
Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes. Mol Pharmacol (2008) 1.04
Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J Neuroinflammation (2004) 1.03
The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol Aging (2011) 1.03
mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. Glia (2012) 1.02
Cellular and pharmacological selectivity of the peroxisome proliferator-activated receptor-beta/delta antagonist GSK3787. Mol Pharmacol (2010) 1.02
Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res (2011) 1.00
Effect of pioglitazone treatment in a patient with secondary multiple sclerosis. J Neuroinflammation (2004) 1.00
The aryl hydrocarbon receptor directly regulates expression of the potent mitogen epiregulin. Toxicol Sci (2005) 0.99
A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res (2009) 0.99
Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis. Carcinogenesis (2008) 0.99
Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs. Mol Carcinog (2009) 0.98
Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J Neurochem (2007) 0.98
Isolation of Bartonella vinsonii subsp. berkhoffii genotype II from a boy with epithelioid hemangioendothelioma and a dog with hemangiopericytoma. J Clin Microbiol (2009) 0.97
Evidence that ligand binding is a key determinant of Ah receptor-mediated transcriptional activity. Arch Biochem Biophys (2005) 0.97